ID   OGT1_HUMAN              Reviewed;        1046 AA.
AC   O15294; Q7Z3K0; Q8WWM8; Q96CC1; Q9UG57;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   21-JUN-2005, sequence version 3.
DT   10-MAY-2017, entry version 192.
DE   RecName: Full=UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit;
DE            EC=2.4.1.255 {ECO:0000269|PubMed:15361863, ECO:0000269|PubMed:19377461, ECO:0000269|PubMed:21240259, ECO:0000269|PubMed:21285374};
DE   AltName: Full=O-GlcNAc transferase subunit p110;
DE   AltName: Full=O-linked N-acetylglucosamine transferase 110 kDa subunit;
DE            Short=OGT;
GN   Name=OGT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PROTEIN SEQUENCE OF 227-236
RP   AND 955-971, AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=9083068; DOI=10.1074/jbc.272.14.9316;
RA   Lubas W.A., Frank D.W., Krause M., Hanover J.A.;
RT   "O-linked GlcNAc transferase is a conserved nucleocytoplasmic protein
RT   containing tetratricopeptide repeats.";
RL   J. Biol. Chem. 272:9316-9324(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1; 2 AND 3).
RX   PubMed=11773972; DOI=10.1007/s00335-001-2108-9;
RA   Nolte D., Muller U.;
RT   "Human O-GlcNAc transferase (OGT): genomic structure, analysis of
RT   splice variants, fine mapping in Xq13.1.";
RL   Mamm. Genome 13:62-64(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4).
RC   TISSUE=Endometrium, Fetal brain, and Spinal cord;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Colon, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 2-17; 31-42; 161-168; 244-250; 339-348; 734-752;
RP   868-877 AND 1002-1010, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION
RP   AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Hepatoma;
RA   Bienvenut W.V., Dhillon A.S., Kolch W.;
RL   Submitted (FEB-2008) to UniProtKB.
RN   [6]
RP   INTERACTION WITH SIN3A, AND FUNCTION.
RX   PubMed=12150998; DOI=10.1016/S0092-8674(02)00810-3;
RA   Yang X., Zhang F., Kudlow J.E.;
RT   "Recruitment of O-GlcNAc transferase to promoters by corepressor
RT   mSin3A: coupling protein O-GlcNAcylation to transcriptional
RT   repression.";
RL   Cell 110:69-80(2002).
RN   [7]
RP   INTERACTION WITH HCFC1.
RX   PubMed=12670868; DOI=10.1101/gad.252103;
RA   Wysocka J., Myers M.P., Laherty C.D., Eisenman R.N., Herr W.;
RT   "Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4
RT   methyltransferase are tethered together selectively by the cell-
RT   proliferation factor HCF-1.";
RL   Genes Dev. 17:896-911(2003).
RN   [8]
RP   SUBCELLULAR LOCATION, FUNCTION, PHOSPHATIDYLINOSITOL-BINDING, AND
RP   MUTAGENESIS OF 991-LYS-LYS-992; ARG-994; LYS-996; LYS-999; ARG-1001
RP   AND LYS-1010.
RX   PubMed=18288188; DOI=10.1038/nature06668;
RA   Yang X., Ongusaha P.P., Miles P.D., Havstad J.C., Zhang F., So W.V.,
RA   Kudlow J.E., Michell R.H., Olefsky J.M., Field S.J., Evans R.M.;
RT   "Phosphoinositide signalling links O-GlcNAc transferase to insulin
RT   resistance.";
RL   Nature 451:964-969(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   FUNCTION, AND ASSOCIATION WITH ALZHEIMER DISEASE.
RX   PubMed=19451179; DOI=10.1093/brain/awp099;
RA   Liu F., Shi J., Tanimukai H., Gu J., Gu J., Grundke-Iqbal I.,
RA   Iqbal K., Gong C.X.;
RT   "Reduced O-GlcNAcylation links lower brain glucose metabolism and tau
RT   pathology in Alzheimer's disease.";
RL   Brain 132:1820-1832(2009).
RN   [12]
RP   INDUCTION.
RX   PubMed=19073609; DOI=10.1074/jbc.M803198200;
RA   Taylor R.P., Geisler T.S., Chambers J.H., McClain D.A.;
RT   "Up-regulation of O-GlcNAc transferase with glucose deprivation in
RT   HepG2 cells is mediated by decreased hexosamine pathway flux.";
RL   J. Biol. Chem. 284:3425-3432(2009).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, AND IDENTIFICATION IN THE MLL5-L
RP   COMPLEX.
RX   PubMed=19377461; DOI=10.1038/nature07954;
RA   Fujiki R., Chikanishi T., Hashiba W., Ito H., Takada I., Roeder R.G.,
RA   Kitagawa H., Kato S.;
RT   "GlcNAcylation of a histone methyltransferase in retinoic-acid-induced
RT   granulopoiesis.";
RL   Nature 459:455-459(2009).
RN   [14]
RP   FUNCTION IN HISTONE H4 ACETYLATION, IDENTIFICATION IN NSL COMPLEX, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=20018852; DOI=10.1074/jbc.C109.087981;
RA   Cai Y., Jin J., Swanson S.K., Cole M.D., Choi S.H., Florens L.,
RA   Washburn M.P., Conaway J.W., Conaway R.C.;
RT   "Subunit composition and substrate specificity of a MOF-containing
RT   histone acetyltransferase distinct from the male-specific lethal (MSL)
RT   complex.";
RL   J. Biol. Chem. 285:4268-4272(2010).
RN   [15]
RP   FUNCTION, AND POSSIBLE ASSOCIATION WITH DIABETES.
RX   PubMed=20018868; DOI=10.1074/jbc.M109.077818;
RA   Whelan S.A., Dias W.B., Thiruneelakantapillai L., Lane M.D.,
RA   Hart G.W.;
RT   "Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-
RT   mediated insulin signaling by O-Linked beta-N-acetylglucosamine in
RT   3T3-L1 adipocytes.";
RL   J. Biol. Chem. 285:5204-5211(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY IN A THAP1/THAP3-HCFC1-OGT
RP   COMPLEX, INTERACTION WITH HCFC1; THAP1 AND THAP3, AND FUNCTION.
RX   PubMed=20200153; DOI=10.1074/jbc.M109.072579;
RA   Mazars R., Gonzalez-de-Peredo A., Cayrol C., Lavigne A.C., Vogel J.L.,
RA   Ortega N., Lacroix C., Gautier V., Huet G., Ray A., Monsarrat B.,
RA   Kristie T.M., Girard J.P.;
RT   "The THAP-zinc finger protein THAP1 associates with coactivator HCF-1
RT   and O-GlcNAc transferase: a link between DYT6 and DYT3 dystonias.";
RL   J. Biol. Chem. 285:13364-13371(2010).
RN   [17]
RP   FUNCTION (ISOFORM 2).
RX   PubMed=20824293; DOI=10.1007/s00726-010-0719-8;
RA   Shin S.H., Love D.C., Hanover J.A.;
RT   "Elevated O-GlcNAc-dependent signaling through inducible mOGT
RT   expression selectively triggers apoptosis.";
RL   Amino Acids 40:885-893(2011).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, UBIQUITINATION,
RP   AND INTERACTION WITH HCFC1.
RX   PubMed=21285374; DOI=10.1073/pnas.1013822108;
RA   Daou S., Mashtalir N., Hammond-Martel I., Pak H., Yu H., Sui G.,
RA   Vogel J.L., Kristie T.M., Affar E.B.;
RT   "Crosstalk between O-GlcNAcylation and proteolytic cleavage regulates
RT   the host cell factor-1 maturation pathway.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:2747-2752(2011).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH H2B.
RX   PubMed=22121020; DOI=10.1038/nature10656;
RA   Fujiki R., Hashiba W., Sekine H., Yokoyama A., Chikanishi T., Ito S.,
RA   Imai Y., Kim J., He H.H., Igarashi K., Kanno J., Ohtake F.,
RA   Kitagawa H., Roeder R.G., Brown M., Kato S.;
RT   "GlcNAcylation of histone H2B facilitates its monoubiquitination.";
RL   Nature 480:557-560(2011).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [22]
RP   FUNCTION.
RX   PubMed=22923583; DOI=10.1126/science.1222278;
RA   Yi W., Clark P.M., Mason D.E., Keenan M.C., Hill C., Goddard W.A. III,
RA   Peters E.C., Driggers E.M., Hsieh-Wilson L.C.;
RT   "Phosphofructokinase 1 glycosylation regulates cell growth and
RT   metabolism.";
RL   Science 337:975-980(2012).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH HCFC1; TET2 AND TET3.
RX   PubMed=23353889; DOI=10.1038/emboj.2012.357;
RA   Deplus R., Delatte B., Schwinn M.K., Defrance M., Mendez J.,
RA   Murphy N., Dawson M.A., Volkmar M., Putmans P., Calonne E., Shih A.H.,
RA   Levine R.L., Bernard O., Mercher T., Solary E., Urh M., Daniels D.L.,
RA   Fuks F.;
RT   "TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT
RT   and SET1/COMPASS.";
RL   EMBO J. 32:645-655(2013).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH TET2 AND TET3.
RX   PubMed=23222540; DOI=10.1038/nature11742;
RA   Chen Q., Chen Y., Bian C., Fujiki R., Yu X.;
RT   "TET2 promotes histone O-GlcNAcylation during gene transcription.";
RL   Nature 493:561-564(2013).
RN   [26]
RP   FUNCTION.
RX   PubMed=24474760; DOI=10.1073/pnas.1323226111;
RA   Chu C.S., Lo P.W., Yeh Y.H., Hsu P.H., Peng S.H., Teng Y.C.,
RA   Kang M.L., Wong C.H., Juan L.J.;
RT   "O-GlcNAcylation regulates EZH2 protein stability and function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:1355-1360(2014).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.85 ANGSTROMS) OF 26-400, FUNCTION, CATALYTIC
RP   ACTIVITY, DOMAIN, AND MUTAGENESIS OF TRP-208 AND ILE-211.
RX   PubMed=15361863; DOI=10.1038/nsmb833;
RA   Jinek M., Rehwinkel J., Lazarus B.D., Izaurralde E., Hanover J.A.,
RA   Conti E.;
RT   "The superhelical TPR-repeat domain of O-linked GlcNAc transferase
RT   exhibits structural similarities to importin alpha.";
RL   Nat. Struct. Mol. Biol. 11:1001-1007(2004).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 323-1041 IN COMPLEXES WITH
RP   UDP AND PEPTIDE SUBSTRATE, FUNCTION, CATALYTIC ACTIVITY, ENZYME
RP   REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, ACTIVE SITE, AND
RP   MUTAGENESIS OF HIS-508; HIS-568 AND HIS-911.
RX   PubMed=21240259; DOI=10.1038/nature09638;
RA   Lazarus M.B., Nam Y., Jiang J., Sliz P., Walker S.;
RT   "Structure of human O-GlcNAc transferase and its complex with a
RT   peptide substrate.";
RL   Nature 469:564-567(2011).
RN   [29]
RP   VARIANT THR-319.
RX   PubMed=26273451; DOI=10.1002/ccr3.301;
RA   Bouazzi H., Lesca G., Trujillo C., Alwasiyah M.K., Munnich A.;
RT   "Nonsyndromic X-linked intellectual deficiency in three brothers with
RT   a novel MED12 missense mutation [c.5922G>T (p.Glu1974His)].";
RL   Clin. Case Rep. 3:604-609(2015).
CC   -!- FUNCTION: Catalyzes the transfer of a single N-acetylglucosamine
CC       from UDP-GlcNAc to a serine or threonine residue in cytoplasmic
CC       and nuclear proteins resulting in their modification with a beta-
CC       linked N-acetylglucosamine (O-GlcNAc). Glycosylates a large and
CC       diverse number of proteins including histone H2B, AKT1, EZH2,
CC       PFKL, KMT2E/MLL5, MAPT/TAU and HCFC1. Can regulate their cellular
CC       processes via cross-talk between glycosylation and phosphorylation
CC       or by affecting proteolytic processing. Involved in insulin
CC       resistance in muscle and adipocyte cells via glycosylating insulin
CC       signaling components and inhibiting the 'Thr-308' phosphorylation
CC       of AKT1, enhancing IRS1 phosphorylation and attenuating insulin
CC       signaling. Involved in glycolysis regulation by mediating
CC       glycosylation of 6-phosphofructokinase PFKL, inhibiting its
CC       activity (PubMed:22923583). Component of a THAP1/THAP3-HCFC1-OGT
CC       complex that is required for the regulation of the transcriptional
CC       activity of RRM1. Plays a key role in chromatin structure by
CC       mediating O-GlcNAcylation of 'Ser-112' of histone H2B: recruited
CC       to CpG-rich transcription start sites of active genes via its
CC       interaction with TET proteins (TET1, TET2 or TET3)
CC       (PubMed:22121020, PubMed:23353889). As part of the NSL complex
CC       indirectly involved in acetylation of nucleosomal histone H4 on
CC       several lysine residues (PubMed:20018852). O-GlcNAcylation of
CC       'Ser-75' of EZH2 increases its stability, and facilitating the
CC       formation of H3K27me3 by the PRC2/EED-EZH2 complex
CC       (PubMed:24474760). Regulates circadian oscillation of the clock
CC       genes and glucose homeostasis in the liver. Stabilizes clock
CC       proteins ARNTL/BMAL1 and CLOCK through O-glycosylation, which
CC       prevents their ubiquitination and subsequent degradation. Promotes
CC       the CLOCK-ARNTL/BMAL1-mediated transcription of genes in the
CC       negative loop of the circadian clock such as PER1/2 and CRY1/2
CC       (PubMed:12150998, PubMed:18288188, PubMed:19377461,
CC       PubMed:19451179, PubMed:20018868, PubMed:20200153,
CC       PubMed:21285374, PubMed:15361863). {ECO:0000269|PubMed:12150998,
CC       ECO:0000269|PubMed:15361863, ECO:0000269|PubMed:18288188,
CC       ECO:0000269|PubMed:19377461, ECO:0000269|PubMed:19451179,
CC       ECO:0000269|PubMed:20018852, ECO:0000269|PubMed:20018868,
CC       ECO:0000269|PubMed:20200153, ECO:0000269|PubMed:21285374,
CC       ECO:0000269|PubMed:22121020, ECO:0000269|PubMed:22923583,
CC       ECO:0000269|PubMed:23353889, ECO:0000269|PubMed:24474760}.
CC   -!- FUNCTION: Isoform 2: the mitochondrial isoform (mOGT) is cytotoxic
CC       and triggers apoptosis in several cell types including INS1, an
CC       insulinoma cell line.
CC   -!- CATALYTIC ACTIVITY: UDP-N-acetyl-alpha-D-glucosamine + [protein]-
CC       L-serine = UDP + [protein]-3-O-(N-acetyl-beta-D-glucosaminyl)-L-
CC       serine. {ECO:0000269|PubMed:15361863, ECO:0000269|PubMed:19377461,
CC       ECO:0000269|PubMed:21240259, ECO:0000269|PubMed:21285374}.
CC   -!- CATALYTIC ACTIVITY: UDP-N-acetyl-alpha-D-glucosamine + [protein]-
CC       L-threonine = UDP + [protein]-3-O-(N-acetyl-beta-D-glucosaminyl)-
CC       L-threonine. {ECO:0000269|PubMed:15361863,
CC       ECO:0000269|PubMed:19377461, ECO:0000269|PubMed:21240259,
CC       ECO:0000269|PubMed:21285374}.
CC   -!- ENZYME REGULATION: Subject to product inhibition by UDP.
CC       {ECO:0000269|PubMed:21240259}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.8 uM for UDP-N-acetyl-D-glucosamine
CC         {ECO:0000269|PubMed:21240259};
CC   -!- PATHWAY: Protein modification; protein glycosylation.
CC   -!- SUBUNIT: Heterotrimer; consists of one 78 kDa subunit and two 110
CC       kDa subunits dimerized via TPR repeats 6 and 7. Interacts (via TPR
CC       repeats 6 and 7) with ATXN10 (By similarity). Component of the
CC       MLL5-L complex, at least composed of KMT2E/MLL5, STK38, PPP1CA,
CC       PPP1CB, HCFC1, PPP1CC and ACTB. Component of a THAP1/THAP3-HCFC1-
CC       OGT complex. Component of the NSL complex at least composed of
CC       MOF/KAT8, KANSL1, KANSL2, KANSL3, MCRS1, PHF20, OGT1/OGT, WDR5 and
CC       HCFC1. Interacts directly with HCFC1; the interaction O-
CC       glycosylates HCFC1, regulates its proteolytic processing and
CC       transcriptional activity and, in turn, stabilizes OGT in the
CC       nucleus. Interacts (via TPRs 1-6) with SIN3A; the interaction
CC       mediates transcriptional repression in parallel with histone
CC       deacetylase. Interacts (via TPR 5-6) with TET1, TET2 and TET3.
CC       Interacts with ARNTL/BMAL1 (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P51610:HCFC1; NbExp=10; IntAct=EBI-539828, EBI-396176;
CC       P09022:Hoxa1 (xeno); NbExp=3; IntAct=EBI-539828, EBI-3957603;
CC       O95644:NFATC1; NbExp=2; IntAct=EBI-539828, EBI-6907210;
CC       Q9H1M0:NUP62CL; NbExp=4; IntAct=EBI-539828, EBI-751933;
CC       Q8NDX5:PHC3; NbExp=3; IntAct=EBI-539828, EBI-1223801;
CC       P36873:PPP1CC; NbExp=11; IntAct=EBI-539828, EBI-356283;
CC       P63088:Ppp1cc (xeno); NbExp=3; IntAct=EBI-539828, EBI-80049;
CC       P11464:PSG1; NbExp=3; IntAct=EBI-539828, EBI-716740;
CC       Q04206:RELA; NbExp=2; IntAct=EBI-539828, EBI-73886;
CC       Q15750:TAB1; NbExp=3; IntAct=EBI-539828, EBI-358643;
CC       E7EQS8:TET2; NbExp=3; IntAct=EBI-539828, EBI-10177000;
CC       Q6N021:TET2; NbExp=7; IntAct=EBI-539828, EBI-310727;
CC       O43151:TET3; NbExp=4; IntAct=EBI-539828, EBI-2831148;
CC       Q8BG87:Tet3 (xeno); NbExp=2; IntAct=EBI-539828, EBI-9031997;
CC       Q9UPV9:TRAK1; NbExp=3; IntAct=EBI-539828, EBI-1105048;
CC       O94763:URI1; NbExp=10; IntAct=EBI-539828, EBI-357067;
CC       O94763-1:URI1; NbExp=3; IntAct=EBI-539828, EBI-12590720;
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Mitochondrion. Membrane.
CC       Note=Associates with the mitochondrial inner membrane.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Cytoplasm. Nucleus. Cell
CC       membrane. Note=Mostly in the nucleus. Retained in the nucleus via
CC       interaction with HCFC1. After insulin induction, translocated from
CC       the nucleus to the cell membrane via phophatidylinisotide binding.
CC       Colocalizes with AKT1 at the plasma membrane.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Cytoplasm. Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=3; Synonyms=Nucleocytoplasmic isoform, ncOGT;
CC         IsoId=O15294-1; Sequence=Displayed;
CC       Name=2; Synonyms=Mitochondrial isoform, mOGT;
CC         IsoId=O15294-2; Sequence=VSP_006553;
CC       Name=1;
CC         IsoId=O15294-3; Sequence=VSP_014164;
CC       Name=4; Synonyms=Short isoform, sOGT;
CC         IsoId=O15294-4; Sequence=VSP_040764;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in pancreas and to a lesser
CC       extent in skeletal muscle, heart, brain and placenta. Present in
CC       trace amounts in lung and liver. {ECO:0000269|PubMed:9083068}.
CC   -!- INDUCTION: Induction of the nucleocytoplasmic OGT (ncOGT) isoform
CC       in the liver on glucose deprivation is mediated by the decreased
CC       hexosamine biosynthesis pathway (HBP) flux.
CC       {ECO:0000269|PubMed:19073609}.
CC   -!- DOMAIN: The TPR repeat domain is required for substrate binding
CC       and oligomerization. {ECO:0000269|PubMed:15361863}.
CC   -!- PTM: Ubiquitinated, leading to its proteasomal degradation.
CC       {ECO:0000269|PubMed:21285374}.
CC   -!- PTM: Phosphorylation on Ser-3 or Ser-4 by GSK3-beta positively
CC       regulates its activity. {ECO:0000250}.
CC   -!- DISEASE: Note=Regulation of OGT activity and altered O-
CC       GlcNAcylations are implicated in diabetes and Alzheimer disease.
CC       O-GlcNAcylation of AKT1 affects insulin signaling and, possibly
CC       diabetes. Reduced O-GlcNAcylations and resulting increased
CC       phosphorylations of MAPT/TAU are observed in Alzheimer disease
CC       (AD) brain cerebrum.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 41 family. O-GlcNAc
CC       transferase subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - GTase; Note=UDP-
CC       N-acetylglucosamine--peptide N-acetylglucosaminyltransferase
CC       110kDa subunit;
CC       URL="http://www.functionalglycomics.org/glycomics/molecule/jsp/glycoEnzyme/viewGlycoEnzyme.jsp?gbpId=gt_hum_554";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U77413; AAB63466.1; -; mRNA.
DR   EMBL; AJ315767; CAC86127.1; -; Genomic_DNA.
DR   EMBL; AJ315767; CAC86128.1; -; Genomic_DNA.
DR   EMBL; AJ315767; CAC86129.1; -; Genomic_DNA.
DR   EMBL; AL050366; CAB62528.1; -; mRNA.
DR   EMBL; AL833085; CAD89970.1; -; mRNA.
DR   EMBL; BX537844; CAD97853.1; -; mRNA.
DR   EMBL; BC014434; AAH14434.1; -; mRNA.
DR   EMBL; BC038180; AAH38180.1; -; mRNA.
DR   CCDS; CCDS14414.1; -. [O15294-1]
DR   CCDS; CCDS35502.1; -. [O15294-3]
DR   RefSeq; NP_858058.1; NM_181672.2. [O15294-1]
DR   RefSeq; NP_858059.1; NM_181673.2. [O15294-3]
DR   RefSeq; XP_016885396.1; XM_017029907.1. [O15294-4]
DR   RefSeq; XP_016885397.1; XM_017029908.1. [O15294-4]
DR   UniGene; Hs.405410; -.
DR   PDB; 1W3B; X-ray; 2.85 A; A/B=26-410.
DR   PDB; 3PE3; X-ray; 2.78 A; A/B/C/D=323-1041.
DR   PDB; 3PE4; X-ray; 1.95 A; A/C=323-1041.
DR   PDB; 3TAX; X-ray; 1.88 A; A/C=323-1041.
DR   PDB; 4AY5; X-ray; 3.15 A; A/B/C/D=323-1041.
DR   PDB; 4AY6; X-ray; 3.30 A; A/B/C/D=323-1041.
DR   PDB; 4CDR; X-ray; 3.15 A; A/B/C/D=323-1041.
DR   PDB; 4GYW; X-ray; 1.70 A; A/C=323-1041.
DR   PDB; 4GYY; X-ray; 1.85 A; A/C=323-1041.
DR   PDB; 4GZ3; X-ray; 1.90 A; A/C=323-1041.
DR   PDB; 4GZ5; X-ray; 3.08 A; A/B/C/D=323-1041.
DR   PDB; 4GZ6; X-ray; 2.98 A; A/B/C/D=323-1041.
DR   PDB; 4N39; X-ray; 1.76 A; A=323-1041.
DR   PDB; 4N3A; X-ray; 1.88 A; A=323-1041.
DR   PDB; 4N3B; X-ray; 2.17 A; A=323-1041.
DR   PDB; 4N3C; X-ray; 2.55 A; A=323-1041.
DR   PDB; 4XI9; X-ray; 3.10 A; A/B/C/D=323-1041.
DR   PDB; 4XIF; X-ray; 3.20 A; A/B/C/D=323-1041.
DR   PDB; 5BNW; X-ray; 2.40 A; A=323-1041.
DR   PDB; 5C1D; X-ray; 2.05 A; A=323-1041.
DR   PDB; 5HGV; X-ray; 2.05 A; A/C=323-1041.
DR   PDBsum; 1W3B; -.
DR   PDBsum; 3PE3; -.
DR   PDBsum; 3PE4; -.
DR   PDBsum; 3TAX; -.
DR   PDBsum; 4AY5; -.
DR   PDBsum; 4AY6; -.
DR   PDBsum; 4CDR; -.
DR   PDBsum; 4GYW; -.
DR   PDBsum; 4GYY; -.
DR   PDBsum; 4GZ3; -.
DR   PDBsum; 4GZ5; -.
DR   PDBsum; 4GZ6; -.
DR   PDBsum; 4N39; -.
DR   PDBsum; 4N3A; -.
DR   PDBsum; 4N3B; -.
DR   PDBsum; 4N3C; -.
DR   PDBsum; 4XI9; -.
DR   PDBsum; 4XIF; -.
DR   PDBsum; 5BNW; -.
DR   PDBsum; 5C1D; -.
DR   PDBsum; 5HGV; -.
DR   ProteinModelPortal; O15294; -.
DR   SMR; O15294; -.
DR   BioGrid; 114049; 99.
DR   DIP; DIP-33491N; -.
DR   IntAct; O15294; 92.
DR   MINT; MINT-2998811; -.
DR   STRING; 9606.ENSP00000362824; -.
DR   BindingDB; O15294; -.
DR   ChEMBL; CHEMBL5955; -.
DR   CAZy; GT41; Glycosyltransferase Family 41.
DR   iPTMnet; O15294; -.
DR   PhosphoSitePlus; O15294; -.
DR   BioMuta; OGT; -.
DR   EPD; O15294; -.
DR   MaxQB; O15294; -.
DR   PaxDb; O15294; -.
DR   PeptideAtlas; O15294; -.
DR   PRIDE; O15294; -.
DR   DNASU; 8473; -.
DR   Ensembl; ENST00000373701; ENSP00000362805; ENSG00000147162. [O15294-3]
DR   Ensembl; ENST00000373719; ENSP00000362824; ENSG00000147162. [O15294-1]
DR   GeneID; 8473; -.
DR   KEGG; hsa:8473; -.
DR   UCSC; uc004eaa.3; human. [O15294-1]
DR   CTD; 8473; -.
DR   DisGeNET; 8473; -.
DR   GeneCards; OGT; -.
DR   HGNC; HGNC:8127; OGT.
DR   HPA; CAB034099; -.
DR   HPA; HPA030751; -.
DR   HPA; HPA030752; -.
DR   HPA; HPA030753; -.
DR   HPA; HPA030754; -.
DR   MIM; 300255; gene.
DR   neXtProt; NX_O15294; -.
DR   OpenTargets; ENSG00000147162; -.
DR   PharmGKB; PA31914; -.
DR   eggNOG; KOG1124; Eukaryota.
DR   eggNOG; KOG4626; Eukaryota.
DR   eggNOG; COG3914; LUCA.
DR   GeneTree; ENSGT00550000074327; -.
DR   HOGENOM; HOG000003765; -.
DR   HOVERGEN; HBG000351; -.
DR   InParanoid; O15294; -.
DR   KO; K09667; -.
DR   OMA; KLAYMPN; -.
DR   OrthoDB; EOG091G024Y; -.
DR   PhylomeDB; O15294; -.
DR   TreeFam; TF105785; -.
DR   BioCyc; MetaCyc:ENSG00000147162-MONOMER; -.
DR   BRENDA; 2.4.1.255; 2681.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-5689603; UCH proteinases.
DR   SABIO-RK; O15294; -.
DR   SignaLink; O15294; -.
DR   SIGNOR; O15294; -.
DR   UniPathway; UPA00378; -.
DR   EvolutionaryTrace; O15294; -.
DR   GeneWiki; OGT_(gene); -.
DR   GenomeRNAi; 8473; -.
DR   PRO; PR:O15294; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000147162; -.
DR   CleanEx; HS_OGT; -.
DR   ExpressionAtlas; O15294; baseline and differential.
DR   Genevisible; O15294; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0000123; C:histone acetyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0008375; F:acetylglucosaminyltransferase activity; TAS:ProtInc.
DR   GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0016262; F:protein N-acetylglucosaminyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0097363; F:protein O-GlcNAc transferase activity; IMP:MGI.
DR   GO; GO:0006915; P:apoptotic process; IDA:UniProtKB.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0080182; P:histone H3-K4 trimethylation; IMP:UniProtKB.
DR   GO; GO:0043984; P:histone H4-K16 acetylation; IDA:UniProtKB.
DR   GO; GO:0043981; P:histone H4-K5 acetylation; IDA:UniProtKB.
DR   GO; GO:0043982; P:histone H4-K8 acetylation; IDA:UniProtKB.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; ISS:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0061087; P:positive regulation of histone H3-K27 methylation; IMP:UniProtKB.
DR   GO; GO:0045862; P:positive regulation of proteolysis; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0006493; P:protein O-linked glycosylation; IDA:UniProtKB.
DR   GO; GO:0090526; P:regulation of gluconeogenesis involved in cellular glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0006110; P:regulation of glycolytic process; IDA:UniProtKB.
DR   GO; GO:0046626; P:regulation of insulin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0035020; P:regulation of Rac protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0032868; P:response to insulin; IDA:UniProtKB.
DR   GO; GO:0007584; P:response to nutrient; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 1.25.40.10; -; 8.
DR   InterPro; IPR029489; OGT/SEC/SPY_C.
DR   InterPro; IPR013026; TPR-contain_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom.
DR   InterPro; IPR001440; TPR_1.
DR   InterPro; IPR019734; TPR_repeat.
DR   Pfam; PF13844; Glyco_transf_41; 1.
DR   Pfam; PF00515; TPR_1; 2.
DR   Pfam; PF13414; TPR_11; 3.
DR   Pfam; PF13181; TPR_8; 2.
DR   SMART; SM00028; TPR; 12.
DR   SUPFAM; SSF48452; SSF48452; 4.
DR   PROSITE; PS50005; TPR; 12.
DR   PROSITE; PS50293; TPR_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   Biological rhythms; Cell membrane; Chromatin regulator;
KW   Complete proteome; Cytoplasm; Direct protein sequencing; Glycoprotein;
KW   Glycosyltransferase; Lipid-binding; Membrane; Mitochondrion; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat; TPR repeat;
KW   Transferase; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.5}.
FT   CHAIN         2   1046       UDP-N-acetylglucosamine--peptide N-
FT                                acetylglucosaminyltransferase 110 kDa
FT                                subunit.
FT                                /FTId=PRO_0000191772.
FT   REPEAT       21     54       TPR 1.
FT   REPEAT       89    122       TPR 2.
FT   REPEAT      123    156       TPR 3.
FT   REPEAT      157    190       TPR 4.
FT   REPEAT      191    224       TPR 5.
FT   REPEAT      225    258       TPR 6.
FT   REPEAT      259    292       TPR 7.
FT   REPEAT      293    326       TPR 8.
FT   REPEAT      327    360       TPR 9.
FT   REPEAT      361    394       TPR 10.
FT   REPEAT      395    428       TPR 11.
FT   REPEAT      429    462       TPR 12.
FT   REPEAT      463    473       TPR 13; truncated.
FT   NP_BIND     905    908       UDP.
FT   NP_BIND     911    914       UDP.
FT   NP_BIND     929    931       UDP.
FT   REGION      991   1010       Required for phosphatidylinositol 3,4,5-
FT                                triphosphate binding.
FT   MOTIF       487    503       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   ACT_SITE    508    508       Proton acceptor.
FT                                {ECO:0000305|PubMed:21240259}.
FT   BINDING     849    849       UDP.
FT   BINDING     852    852       UDP.
FT   BINDING     935    935       UDP.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.5}.
FT   MOD_RES       3      3       Phosphoserine; by GSK3-beta; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES       4      4       Phosphoserine; by GSK3-beta; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES      20     20       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CARBOHYD      3      3       O-linked (GlcNAc) serine; alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD      4      4       O-linked (GlcNAc) serine; alternate.
FT                                {ECO:0000250}.
FT   VAR_SEQ       1    381       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_040764.
FT   VAR_SEQ       1    176       MASSVGNVADSTEPTKRMLSFQGLAELAHREYQAGDFEAAE
FT                                RHCMQLWRQEPDNTGVLLLLSSIHFQCRRLDRSAHFSTLAI
FT                                KQNPLLAEAYSNLGNVYKERGQLQEAIEHYRHALRLKPDFI
FT                                DGYINLAAALVAAGDMEGAVQAYVSALQYNPDLYCVRSDLG
FT                                NLLKALGRLEEA -> MLQGHFWLVREGIMISPSSPPPPNL
FT                                FFFPLQIFPFPFTSFPSHLLSLTPP (in isoform 2).
FT                                {ECO:0000303|PubMed:9083068}.
FT                                /FTId=VSP_006553.
FT   VAR_SEQ      13     22       Missing (in isoform 1).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_014164.
FT   VARIANT     319    319       A -> T (probable disease-associated
FT                                mutation found in a family with X-linked
FT                                intellectual disability).
FT                                {ECO:0000269|PubMed:26273451}.
FT                                /FTId=VAR_074019.
FT   VARIANT     538    538       L -> P (found in a renal cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_064736.
FT   MUTAGEN     208    208       W->E: Abolishes homodimerization of the
FT                                TPR domain. Slightly reduced enzyme
FT                                activity; when associated with D-211.
FT                                {ECO:0000269|PubMed:15361863}.
FT   MUTAGEN     211    211       I->D: Abolishes homodimerization of the
FT                                TPR domain. Slightly reduced enzyme
FT                                activity; when associated with E-208.
FT                                {ECO:0000269|PubMed:15361863}.
FT   MUTAGEN     508    508       H->A: Loss of enzyme activity.
FT                                {ECO:0000269|PubMed:21240259}.
FT   MUTAGEN     568    568       H->A: Reduces enzyme activity by about
FT                                95%. {ECO:0000269|PubMed:21240259}.
FT   MUTAGEN     911    911       H->A: Reduces enzyme activity by over
FT                                90%. {ECO:0000269|PubMed:21240259}.
FT   MUTAGEN     991    992       KK->AA: Abolishes phosphatidylinisitol
FT                                binding, no translocation to the cell
FT                                membrane, and no effect on
FT                                phosphorylation of AKT1 nor IRS1.
FT                                {ECO:0000269|PubMed:18288188}.
FT   MUTAGEN     994    994       R->A: No effect on phosphatidylinisitol
FT                                binding. {ECO:0000269|PubMed:18288188}.
FT   MUTAGEN     996    996       K->A: Reduced phosphatidylinisitol
FT                                binding. {ECO:0000269|PubMed:18288188}.
FT   MUTAGEN     999    999       K->A: Reduced phosphatidylinisitol
FT                                binding. {ECO:0000269|PubMed:18288188}.
FT   MUTAGEN    1001   1001       R->A: No effect on phosphatidylinisitol
FT                                binding. {ECO:0000269|PubMed:18288188}.
FT   MUTAGEN    1010   1010       K->A: No effect on phosphatidylinisitol
FT                                binding. {ECO:0000269|PubMed:18288188}.
FT   CONFLICT    308    308       S -> Q (in Ref. 3; CAB62528).
FT                                {ECO:0000305}.
FT   CONFLICT    663    663       L -> P (in Ref. 3; CAD97853).
FT                                {ECO:0000305}.
FT   HELIX        27     34       {ECO:0000244|PDB:1W3B}.
FT   HELIX        37     50       {ECO:0000244|PDB:1W3B}.
FT   HELIX        55     67       {ECO:0000244|PDB:1W3B}.
FT   HELIX        71     84       {ECO:0000244|PDB:1W3B}.
FT   HELIX        89    102       {ECO:0000244|PDB:1W3B}.
FT   HELIX       105    118       {ECO:0000244|PDB:1W3B}.
FT   HELIX       123    136       {ECO:0000244|PDB:1W3B}.
FT   HELIX       141    152       {ECO:0000244|PDB:1W3B}.
FT   HELIX       158    168       {ECO:0000244|PDB:1W3B}.
FT   HELIX       173    186       {ECO:0000244|PDB:1W3B}.
FT   HELIX       191    202       {ECO:0000244|PDB:1W3B}.
FT   TURN        203    205       {ECO:0000244|PDB:1W3B}.
FT   HELIX       207    220       {ECO:0000244|PDB:1W3B}.
FT   HELIX       225    236       {ECO:0000244|PDB:1W3B}.
FT   TURN        237    239       {ECO:0000244|PDB:1W3B}.
FT   HELIX       243    254       {ECO:0000244|PDB:1W3B}.
FT   HELIX       259    271       {ECO:0000244|PDB:1W3B}.
FT   HELIX       275    287       {ECO:0000244|PDB:1W3B}.
FT   HELIX       293    306       {ECO:0000244|PDB:1W3B}.
FT   HELIX       309    322       {ECO:0000244|PDB:1W3B}.
FT   HELIX       325    339       {ECO:0000244|PDB:4GYW}.
FT   HELIX       343    356       {ECO:0000244|PDB:4GYW}.
FT   HELIX       361    373       {ECO:0000244|PDB:4GYW}.
FT   HELIX       377    390       {ECO:0000244|PDB:4GYW}.
FT   HELIX       395    407       {ECO:0000244|PDB:4GYW}.
FT   HELIX       411    424       {ECO:0000244|PDB:4GYW}.
FT   HELIX       429    441       {ECO:0000244|PDB:4GYW}.
FT   HELIX       445    458       {ECO:0000244|PDB:4GYW}.
FT   HELIX       463    475       {ECO:0000244|PDB:4GYW}.
FT   HELIX       482    498       {ECO:0000244|PDB:4GYW}.
FT   HELIX       509    512       {ECO:0000244|PDB:4GYW}.
FT   HELIX       517    536       {ECO:0000244|PDB:4GYW}.
FT   TURN        537    539       {ECO:0000244|PDB:3TAX}.
FT   STRAND      547    549       {ECO:0000244|PDB:4N39}.
FT   TURN        550    554       {ECO:0000244|PDB:4GYW}.
FT   STRAND      556    563       {ECO:0000244|PDB:4GYW}.
FT   STRAND      565    568       {ECO:0000244|PDB:4GYW}.
FT   HELIX       569    574       {ECO:0000244|PDB:4GYW}.
FT   HELIX       577    580       {ECO:0000244|PDB:4GYW}.
FT   TURN        583    585       {ECO:0000244|PDB:4GYW}.
FT   STRAND      586    594       {ECO:0000244|PDB:4GYW}.
FT   HELIX       600    608       {ECO:0000244|PDB:4GYW}.
FT   STRAND      609    614       {ECO:0000244|PDB:4GYW}.
FT   HELIX       615    617       {ECO:0000244|PDB:4GYW}.
FT   HELIX       621    630       {ECO:0000244|PDB:4GYW}.
FT   STRAND      634    639       {ECO:0000244|PDB:4GYW}.
FT   STRAND      641    643       {ECO:0000244|PDB:4GYW}.
FT   HELIX       649    652       {ECO:0000244|PDB:4GYW}.
FT   STRAND      656    661       {ECO:0000244|PDB:4GYW}.
FT   STRAND      676    679       {ECO:0000244|PDB:4GYW}.
FT   TURN        681    683       {ECO:0000244|PDB:4GYW}.
FT   HELIX       686    691       {ECO:0000244|PDB:4GYW}.
FT   STRAND      693    698       {ECO:0000244|PDB:4GYW}.
FT   HELIX       708    711       {ECO:0000244|PDB:4GYW}.
FT   HELIX       713    715       {ECO:0000244|PDB:4GYW}.
FT   STRAND      719    721       {ECO:0000244|PDB:4GYW}.
FT   STRAND      731    737       {ECO:0000244|PDB:4GYW}.
FT   HELIX       741    746       {ECO:0000244|PDB:4GYW}.
FT   STRAND      748    750       {ECO:0000244|PDB:4GYW}.
FT   STRAND      752    754       {ECO:0000244|PDB:4GYW}.
FT   STRAND      774    777       {ECO:0000244|PDB:4GYW}.
FT   HELIX       781    792       {ECO:0000244|PDB:4GYW}.
FT   STRAND      796    799       {ECO:0000244|PDB:4GYW}.
FT   STRAND      802    806       {ECO:0000244|PDB:4GYW}.
FT   HELIX       807    809       {ECO:0000244|PDB:4GYY}.
FT   HELIX       810    813       {ECO:0000244|PDB:4GYW}.
FT   HELIX       815    818       {ECO:0000244|PDB:4GYW}.
FT   STRAND      820    822       {ECO:0000244|PDB:4AY5}.
FT   STRAND      826    831       {ECO:0000244|PDB:4GYW}.
FT   HELIX       832    835       {ECO:0000244|PDB:4GYW}.
FT   STRAND      841    845       {ECO:0000244|PDB:4GYW}.
FT   HELIX       850    852       {ECO:0000244|PDB:4GYW}.
FT   HELIX       855    867       {ECO:0000244|PDB:4GYW}.
FT   STRAND      869    877       {ECO:0000244|PDB:4GYW}.
FT   HELIX       880    882       {ECO:0000244|PDB:4GYW}.
FT   HELIX       883    892       {ECO:0000244|PDB:4GYW}.
FT   HELIX       897    899       {ECO:0000244|PDB:4GYW}.
FT   STRAND      900    904       {ECO:0000244|PDB:4GYW}.
FT   HELIX       908    914       {ECO:0000244|PDB:4GYW}.
FT   HELIX       915    917       {ECO:0000244|PDB:4GYW}.
FT   STRAND      919    922       {ECO:0000244|PDB:4GYW}.
FT   STRAND      925    927       {ECO:0000244|PDB:4GYW}.
FT   HELIX       931    938       {ECO:0000244|PDB:4GYW}.
FT   STRAND      943    945       {ECO:0000244|PDB:4GYW}.
FT   HELIX       951    953       {ECO:0000244|PDB:4GYW}.
FT   HELIX       955    963       {ECO:0000244|PDB:4GYW}.
FT   HELIX       966    968       {ECO:0000244|PDB:4GYW}.
FT   HELIX       973    985       {ECO:0000244|PDB:4GYW}.
FT   HELIX       987   1003       {ECO:0000244|PDB:4GYW}.
FT   HELIX      1005   1007       {ECO:0000244|PDB:4N3C}.
FT   HELIX      1009   1028       {ECO:0000244|PDB:4GYW}.
SQ   SEQUENCE   1046 AA;  116925 MW;  852ED68BDDE63363 CRC64;
     MASSVGNVAD STEPTKRMLS FQGLAELAHR EYQAGDFEAA ERHCMQLWRQ EPDNTGVLLL
     LSSIHFQCRR LDRSAHFSTL AIKQNPLLAE AYSNLGNVYK ERGQLQEAIE HYRHALRLKP
     DFIDGYINLA AALVAAGDME GAVQAYVSAL QYNPDLYCVR SDLGNLLKAL GRLEEAKACY
     LKAIETQPNF AVAWSNLGCV FNAQGEIWLA IHHFEKAVTL DPNFLDAYIN LGNVLKEARI
     FDRAVAAYLR ALSLSPNHAV VHGNLACVYY EQGLIDLAID TYRRAIELQP HFPDAYCNLA
     NALKEKGSVA EAEDCYNTAL RLCPTHADSL NNLANIKREQ GNIEEAVRLY RKALEVFPEF
     AAAHSNLASV LQQQGKLQEA LMHYKEAIRI SPTFADAYSN MGNTLKEMQD VQGALQCYTR
     AIQINPAFAD AHSNLASIHK DSGNIPEAIA SYRTALKLKP DFPDAYCNLA HCLQIVCDWT
     DYDERMKKLV SIVADQLEKN RLPSVHPHHS MLYPLSHGFR KAIAERHGNL CLDKINVLHK
     PPYEHPKDLK LSDGRLRVGY VSSDFGNHPT SHLMQSIPGM HNPDKFEVFC YALSPDDGTN
     FRVKVMAEAN HFIDLSQIPC NGKAADRIHQ DGIHILVNMN GYTKGARNEL FALRPAPIQA
     MWLGYPGTSG ALFMDYIITD QETSPAEVAE QYSEKLAYMP HTFFIGDHAN MFPHLKKKAV
     IDFKSNGHIY DNRIVLNGID LKAFLDSLPD VKIVKMKCPD GGDNADSSNT ALNMPVIPMN
     TIAEAVIEMI NRGQIQITIN GFSISNGLAT TQINNKAATG EEVPRTIIVT TRSQYGLPED
     AIVYCNFNQL YKIDPSTLQM WANILKRVPN SVLWLLRFPA VGEPNIQQYA QNMGLPQNRI
     IFSPVAPKEE HVRRGQLADV CLDTPLCNGH TTGMDVLWAG TPMVTMPGET LASRVAASQL
     TCLGCLELIA KNRQEYEDIA VKLGTDLEYL KKVRGKVWKQ RISSPLFNTK QYTMELERLY
     LQMWEHYAAG NKPDHMIKPV EVTESA
//
